Eurofins Genomics Europe Pharma and Diagnostics Products & Services Synthesis GmbH, based in Ebersberg, is specialized in the production of synthetic oligonucleotides. The products are sold to end customers in research and diagnostics and are typically ordered individually by researchers and developers via the internet. The company operates within the Eurofins group and is included in the consolidated group with Eurofins Scientific S.E., Luxembourg, as the parent company. In fiscal year 2024 the company had an average of 93 employees and performs both production and distribution functions for DNA synthesis products.
Entwicklung, Synthese, Analyse und Vertrieb von Substanzen oder Geräten im Bereich Molekularbiologie, insbesondere für die pharmazeutische und diagnostische Industrie.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 165839 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Ulrich Kühle | Geschäftsführer(in) | Hamburg |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 165839 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€12.9M2 | -€4,579,873 | €16,696,042 | — |
| 2024 | Rohergebnis€9.9M2 | -€6,949,111 | €20,953,540 | — |
| 2023 | Rohergebnis€8.8M2 | -€10,322,044 | €19,382,818 | — |
| 2022 | Rohergebnis€8.6M2 | -€10,743,055 | €29,015,105 | — |
| 2021 | Rohergebnis€19.9M2 | €4,384,913 | €27,754,789 | — |
| 2020 | Rohergebnis€9.3M2 | -€852,097 | €12,737,361 | — |
| 2019 | Rohergebnis€9.9M2 | €0 | €10,528,900 | — |
| 2018 | Rohergebnis€9M2 | €785,965 | €8,384,189 | — |
| 2017 | Rohergebnis€10.3M2 | €2,643,356 | €5,723,371 | — |
| 2016 | Rohergebnis€10.2M2 | €1,827,005 | €4,244,725 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 165839 (as of 1 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €6,239,226 | 77.1% |
| Depreciation | €1,400,547 | 17.3% |
| Interest & Similar | €447,943 | 5.5% |
